43. ElevateBio
Founders: David Hallal, Vikas Sinha, Mitchell FinerCEO: Ger BrophyLaunched: 2017Headquarters: Waltham, MassachusettsFunding: $1.3 billionValuation: N/AKey Technologies: N/AIndustry: BiotechPrevious appearances on Disruptor 50 list: 3 (No. 8 in 2024)
In the face of significant headwinds for the biotech sector over the past year, ElevateBio has continued to advance its research related to the breakthrough CRISPR gene editing technology, and treatments ranging from cancer, to multiple sclerosis, diabetes, and Huntington's Disease.
In March, the company partnered with Amazon Web Services to combine its advanced computing power with ElevateBio's patented gene editing platform. The collaboration will enable ElevateBio to analyze data to design new CRISPR systems more efficiently using generative AI. That efficiency could enable genetic treatments for many more diseases caused by complex genetic mutations, as the FDA ramps up its approvals pace for gene therapies to 10-20 a year.
ElevateBio develops its own therapeutics, but is also helping other companies scale their therapeutics production, by offering manufacturing services to companies such as Moderna and Novo Nordisk, with which it has expanded a therapeutic pipeline to 10-plus internal & partnered gene editing programs. ElevateBio's partnerships with Novo Nordisk and Moderna include revenue from products developed through its Life Edit gene editing platform.
ElevateBio has a manufacturing plant at its Waltham Mass., headquarters. In 2027, the company will start operating a new plant in Pittsburgh, Pa., built with the help of a record $100 million grant from the Richard King Mellon Foundation. Call them one-stop shops for some of the most advanced therapeutics in the world.
The company, which stayed in stealth mode for two years after its founding in 2017 by industry veteran David Hallal, competes in a fast-growing field, from big pharmas to companies such as CRISPR Therapeutics and Bluebird Bio. Coming in addition to other advances, such as mRNA vaccines, the CRISPR technology makes it promising time to be a biotech company. But Bluebird's recent fall from a multi-billion dollar public valuation to private equity sale for a reported $29 million demonstrates that along with the promise, there will always be a high-risk nature to these efforts.
ElevateBio says it achieved $120 million in 2024 annual revenue, with 200%-plus growth over two years, and is projecting growth of 30%-plus year-over-year in 2025. But it also has experienced growing pains amid the biotech sector pressures, with a recent round of layoffs affecting 17% of its workforce.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Moderna receives FDA approval for RSV vaccine
The company states: 'Moderna (MRNA) announced that the FDA has approved mRESVIA, or mRNA-1345, the company's respiratory syncytial virus, RSV, vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. hile the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease, with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults. This approval was supported by results from Moderna's Phase 3 study, which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season.'
Yahoo
an hour ago
- Yahoo
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
In the latest close session, Novo Nordisk (NVO) was up +2.95% at $81.05. This move outpaced the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Heading into today, shares of the drugmaker had gained 22.23% over the past month, outpacing the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%. The upcoming earnings release of Novo Nordisk will be of great interest to investors. The company is forecasted to report an EPS of $0.88, showcasing a 35.38% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $11.73 billion, indicating a 19.45% growth compared to the corresponding quarter of the prior year. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.84 per share and revenue of $47.95 billion. These totals would mark changes of +17.07% and +13.91%, respectively, from last year. Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.42% lower. Novo Nordisk is currently sporting a Zacks Rank of #3 (Hold). In terms of valuation, Novo Nordisk is currently trading at a Forward P/E ratio of 20.52. This denotes a premium relative to the industry average Forward P/E of 13.81. Meanwhile, NVO's PEG ratio is currently 1.42. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.27 at the close of the market yesterday. The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 36, placing it within the top 15% of over 250 industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
4 hours ago
COVID-19 patients with reduced kidney function who are vaccinated are more likely to survive: Study
Patients vaccinated against COVID-19 who caught the virus -- and were hospitalized with reduced kidney function -- had better outcomes than unvaccinated patients with the same conditions, a new study has found. Vaccinated patients were less likely to need dialysis after being discharged from the hospital and were more likely to survive, according to the study. Lead author Dr. Niloofar Nobakht, a health sciences clinical associate professor of medicine in the division of nephrology at UCLA's David Geffen School of Medicine, said the findings suggest COVID-19 vaccination can reduce the risk of long-term kidney function decline and of death. "The COVID-19 vaccine is an important intervention that can decrease the chances of developing complications from the COVID-19 infection in patients hospitalized with acute kidney injuries," Nobakht said in a news release. "It is important for individuals to discuss the benefits of getting vaccinated for COVID-19 with their doctors as it can decrease the chances of needing dialysis, which can severely affect the quality of life of patients and lead to further complications, including death," she continued. For the study, published early Friday in the journal Kidney Medicine, researchers looked at about 3,500 patients who were hospitalized with COVID-19 between March 1, 2020, and March 30, 2022. Of those patients, 972 developed acute kidney injury, which is a sudden reduction in kidney function, with 411 who were unvaccinated against COVID-19 and 467 who were vaccinated. Vaccinated patients received either at least two doses of the Pfizer-BioNTech or Moderna vaccines or one dose of the Johnson & Johnson vaccine. Nearly 16% of unvaccinated patients needed a form of dialysis known as continuous renal replacement therapy (CRRT) -- a continuous, slow-motion dialysis that runs 24 hours a day -- compared with about 11% of vaccinated patients. Results also showed unvaccinated patients were 2.56 times more likely to need CRRT after being discharged from the hospital and 5.54 times more likely to die in the hospital compared to vaccinated patients. Additionally, those who were unvaccinated were 4.78 times more likely to die during long-term follow-up. "This study also emphasizes the importance of the need for continued research in understanding how COVID-19 infections affect the kidney and how we should manage and monitor kidney complications from COVID-19 infections to improve patient outcomes," Nobakht said. The authors said one of the limitations of the study was not enough data on the severity of COVID-19 illness, but the team did note all the patients were ill enough to have required hospitalization. The new study comes as COVID-19 vaccines have received renewed attention due to recent moves from Health and Human Services Secretary Robert F. Kennedy Jr. Last month, Kennedy announced COVID-19 vaccines were being removed from the Centers for Disease Control and Prevention's immunization schedule for "healthy children and pregnant women." Additionally, earlier this week, Kennedy removed all 17 sitting members of the CDC's independent vaccine advisory committee and appointed eight replacement members, some of whom have shared vaccine-skeptic views.
